Back to Search

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer


  • Protocol Number: 202008047
  • Principal Investigator: Waqar, Saiama
  • Cancer Types: Lung

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions